What is a stock summary page? Click here for an overview.
Business Description
Beryl Drugs Ltd
ISIN : INE415H01017
Share Class Description:
BOM:524606: Shs DematerialisedCompare
Compare
Traded in other countries / regions
524606.India IPO Date
1994-09-05Description
Beryl Drugs Ltd is a pharmaceutical company principally engaged in the manufacturing and marketing of allopathic pharmaceutical preparations. It also provides contract manufacturing services and veterinary products. It offers manufacturing options for product requirements like small-volume injectables in liquid form, small-volume injectables in dry powder form, eye and ear drops, intravenous fluids in poly pack and glass bottles, and veterinary medicines. The company earns the majority of its revenue from the sale of Bulk Drugs.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.06 | |||||
| Equity-to-Asset | 0.55 | |||||
| Debt-to-Equity | 0.49 | |||||
| Debt-to-EBITDA | 2.1 | |||||
| Interest Coverage | 1.11 | |||||
| Piotroski F-Score | 9/9 | |||||
| Altman Z-Score | 2.54 | |||||
| Beneish M-Score | -2.44 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 24.1 | |||||
| 3-Year EBITDA Growth Rate | 9.1 | |||||
| 3-Year FCF Growth Rate | 9.4 | |||||
| 3-Year Book Growth Rate | 4 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 57.87 | |||||
| 9-Day RSI | 51.21 | |||||
| 14-Day RSI | 47.07 | |||||
| 3-1 Month Momentum % | -33.35 | |||||
| 6-1 Month Momentum % | -37.35 | |||||
| 12-1 Month Momentum % | -32.8 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.91 | |||||
| Quick Ratio | 1.64 | |||||
| Cash Ratio | 0.06 | |||||
| Days Inventory | 27.65 | |||||
| Days Sales Outstanding | 146.1 | |||||
| Days Payable | 49.87 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -0.53 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 21.41 | |||||
| Operating Margin % | 3.17 | |||||
| Net Margin % | 0.4 | |||||
| FCF Margin % | -2.68 | |||||
| ROE % | 0.88 | |||||
| ROA % | 0.45 | |||||
| ROIC % | 0.99 | |||||
| 3-Year ROIIC % | 168.99 | |||||
| ROC (Joel Greenblatt) % | 7.27 | |||||
| ROCE % | 7.59 | |||||
| Years of Profitability over Past 10-Year | 8 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 143.56 | |||||
| PE Ratio without NRI | 143.56 | |||||
| Shiller PE Ratio | 22.92 | |||||
| PEG Ratio | 10.4 | |||||
| PS Ratio | 0.59 | |||||
| PB Ratio | 1.26 | |||||
| Price-to-Tangible-Book | 1.25 | |||||
| Price-to-Operating-Cash-Flow | 14.2 | |||||
| EV-to-EBIT | 17.49 | |||||
| EV-to-EBITDA | 7.39 | |||||
| EV-to-Revenue | 0.8 | |||||
| EV-to-FCF | -29.71 | |||||
| Price-to-GF-Value | 1.6 | |||||
| Price-to-Median-PS-Value | 1.51 | |||||
| Price-to-Peter-Lynch-Fair-Value | 7.87 | |||||
| Price-to-Graham-Number | 1.38 | |||||
| Price-to-Net-Current-Asset-Value | 9.22 | |||||
| Earnings Yield (Greenblatt) % | 5.72 | |||||
| FCF Yield % | -4.56 | |||||
| Forward Rate of Return (Yacktman) % | 18.28 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Beryl Drugs Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 198.652 | ||
| EPS (TTM) (₹) | 0.16 | ||
| Beta | 0.43 | ||
| 3-Year Sharpe Ratio | 0.55 | ||
| 3-Year Sortino Ratio | 1.04 | ||
| Volatility % | 52.42 | ||
| 14-Day RSI | 47.07 | ||
| 14-Day ATR (₹) | 1.649063 | ||
| 20-Day SMA (₹) | 22.595 | ||
| 12-1 Month Momentum % | -32.8 | ||
| 52-Week Range (₹) | 20.27 - 46 | ||
| Shares Outstanding (Mil) | 5.07 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Beryl Drugs Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Beryl Drugs Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Beryl Drugs Ltd Frequently Asked Questions
What is Beryl Drugs Ltd(BOM:524606)'s stock price today?
The current price of BOM:524606 is ₹22.97. The 52 week high of BOM:524606 is ₹46.00 and 52 week low is ₹20.27.
When is next earnings date of Beryl Drugs Ltd(BOM:524606)?
The next earnings date of Beryl Drugs Ltd(BOM:524606) is .
Does Beryl Drugs Ltd(BOM:524606) pay dividends? If so, how much?
Beryl Drugs Ltd(BOM:524606) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers